ANAFRANIL SR 75 Milligram Tablets

Ireland - English - HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:
CLOMIPRAMINE HYDROCHLORIDE
Available from:
Novartis Pharmaceuticals UK Ltd
ATC code:
N06AA04
INN (International Name):
CLOMIPRAMINE HYDROCHLORIDE
Dosage:
75 Milligram
Pharmaceutical form:
Tablets
Prescription type:
Product subject to prescription which may not be renewed (A)
Therapeutic area:
Non-selective monoamine reuptake inhibitors
Authorization status:
Authorised
Authorization number:
PA0013/084/006
Authorization date:
1993-09-19

Package leaflet:

Informationforthe user

ANAFRANIL

® SR

75 mgprolonged releaseTablets

Clomipramine hydrochloride

Thismedicine willbe referred toasAnafranilin thisleaflet.

Read all ofthis informationcarefullybeforeyoustarttakingthismedicine.

Keepthisleaflet. You mayneedto read it again.

Ifyou have furtherquestions, askyour doctor orpharmacist.

Thismedicine hasbeen prescribedfor you. Donotpassit onto others. It mayharmthem, even iftheir

symptomsare the same asyours.

Ifanyoftheside effectsgetserious, or ifyou notice anyside effectsnotlisted in thisleaflet, please tellyour

doctor orpharmacist.

In this leaflet

1.What Anafranilisandwhat it isusedfor

2. Before you take Anafranil

3. How totakeAnafranil

4. Possible side effects

5. How tostore Anafranil

6. Further information

1. WhatAnafranil isandwhat itisused for

Anafranilcontainsa medicine calledclomipramine hydrochloride. Thisbelongsto agroup ofmedicines

called “tricyclicantidepressants”. Anafranilisthought to workeither byincreasing the amountofchemical

“messengers”in thebrain orbymaking theireffectslast longer.

Anafranilisused totreat depression, obsessionsandphobias(irrationalfears). It isalso used totreatmuscular

weakness(cataplexy)associatedwith repeat attacksofextreme sleepiness(narcolepsy)in adults.

2. BeforeyoutakeAnafranil

DonottakeAnafranil if:

you are allergic(hypersensitive) to clomipramine oranyoftheotheringredientsofAnafranil(listedin Section

6 below)

you have ever had arash or other allergicreaction toanyotherantidepressants

you have had a heart attackwithin thelast 3 months

you have anyseriousheart disease

you have anyseriousliver disease

youhave anyothermentalillnessapart fromdepression, obsessionsor phobias

you have glaucoma(increased eye pressure)

you have difficultyin passing urine

you are pregnant,might become pregnant orare breast-feeding

you are aged under 18

you aretaking medicinesfor depression called monoamine oxidase inhibitors(MAOIs), or have taken them

within thelast 3 weeks.

Do nottake Anafranilifanyoftheabove applyto you. Ifyou are not sure, talkto yourdoctor orpharmacist

before taking Anafranil.

Takespecial carewithAnafranil

Checkwith your doctor orpharmacist before taking your medicine if:

you have epilepsy(fits)

you have anoveractive thyroid gland

you have a tumour(cancer)oftheadrenalgland(such asphaeochromocytoma or neuroblastoma)

you have low bloodpressure

you wearcontact lenses

you have had severe constipation for a longtime

you find yourselfthinking aboutsuicide

you have had a headinjuryandsuffered brain damage

you are going tohave ECT(electroconvulsive therapy)

you have anirregular heartbeator other problemswith your heart

you have been diagnosed ashaving alow levelofpotassiumin your blood(hypokalemia)

you have schizophrenia oranyothermentaldisorder

you are elderly

youhave glaucoma(increased pressure in theeye)

you have liver orkidneydisease

you have anyblooddisorder

you have difficultiesin passing urine (e.g. due todiseasesoftheprostate)

you easilyfaint

Ifanyoftheabove applyto you (oryouarenot sure), talkto your doctor orpharmacist before taking Anafranil.

Takingothermedicines

Please tellyour doctor orpharmacist ifyou are taking orhave recentlytaken anyothermedicines.

Thisincludesmedicinesobtainedwithout a prescription,including herbalmedicines. Anafranilinteracts

with alarge number ofmedicines.

In particular, do nottake Anafranilifyou are taking the following:

medicinesfor depressioncalled monoamine oxidase inhibitors(MAOIs), or have taken themwithin thelast 3

weeks.

Do nottake Anafranilifthisappliesto you. Ifyou are not sure, talkto your doctor orpharmacist before taking

Anafranil.

Tellyour doctor ifyou are taking anyofthefollowing:

othermedicinesfor depression called SSRIse.g.fluoxetine, fluvoxamine; tricyclicantidepressants

e.g. barbiturates, benzodiazepines

medicinesfor other mentalillnessessuch asschizophrenia or manicdepression e.g. thioridazine, lithium

medicinesfor high bloodpressure

medicinesto treat heart disorders, particularlythose used totreat an abnormalheartrhythm

anticoagulants(bloodthinning tabletslike warfarin)

medicinesfor Parkinson’sDisease

drugswhich affect theliver (your doctorwillknow whichthese are). Theyincludenicotine and barbiturates

cold,flu or hayfever drugssuch asantihistaminesanddecongestants

carbamazepine orphenytoin (for epilepsy)

cimetidine (forstomach problems)

methylphenidate(Ritalin) prescribedfor children with ADHD

atropine orsimilar medicines(includingeye drops)

estrogens(e.g.contraceptive pillor hormonereplacement therapy)

a medicine called terbinafine (used orallyto treat skin, hairor nailinfectionsduetofungus)

drugsused toreduce fatinblood

grapefruit/grapefruitjuice, cranberryjuice

Ifanyoftheabove applyto you (oryouare not sure), talkto your doctor orpharmacist before taking Anafranil.

Operations, tests andcheck-ups

Tellyour doctor ordentist if you are planning tohave anoperation ofanykind, asAnafranilmayinteract

with localor generalanaesthetic.

Your doctormaywant to dobloodtestsandcheckyour heart and liver function whileyou are taking Anafranil.

You should goto the dentist regularlyifyou take Anafranilfor a longtime. Anafranilcan cause a drymouth

which mayincrease thechance oftooth decay.

TakingAnafranil withfoodandalcohol

You should not drinkalcoholduring your treatment withAnafranil–it mayaffect you more thanusual.

You can take Anafranilwithor without food

Pregnancyandbreast-feeding

Do nottake Anafranilifyou are pregnant ormight becomepregnant.Do not take Anafranilifyou are breast-

feeding.

Askyour doctor orpharmacist for advice before taking anymedicine, ifyou are pregnant, might become

pregnant orare breast-feeding.

Drivingandusingmachines

Ifyou feeldizzy, tired orhave blurred vision when you start to take Anafranil, donot drive or workwith

machineryuntilthiseffect hasworn off.

Importantinformationaboutsome ofthe ingredientsofAnafranil

Anafraniltabletscontain polyoxylhydrogenated castor oilwhich maycause stomach upset and diarrhoea.

Informationforyou,yourfamilyandcaregivers

Informationforyou

Ifyou are depressed orhaveanxietydisordersyou can sometimeshave thoughtsofharming orkilling yourself.

These maybe increased when you first start taking antidepressants, since these medicinesalltake time to

work, usuallyabout twoweeksbutsometimeslonger.

Youmaybe more likelyto have these thoughtsif:

ifyou have previouslyhadthoughtsabout killing orharming yourself

ifyou are a youngadult. Information fromclinicaltrialshasshown an increased riskofsuicidalbehaviour in

adultsaged lessthan25 yearswith psychiatricconditionswho were treated with anantidepressant.

Ifyou have thoughtofharming orkilling yourselfat anytime,contactyourdoctororgotoahospital straight

away. You mayfind it helpfulto tella relative or closefriend that you are depressed orhave ananxiety

disorder,

andaskthemto read thisleaflet. You might askthemto tellyou iftheythinkyour depression oranxietyis

getting worse, or iftheyare worried aboutchangesin your behaviour.

Informationforyourfamily andcaregivers

The patient should bemonitored tosee iftheyshow signsofbehaviouralchangessuchasunusualanxiety,

restlessness, sleeping problems, irritability, aggressiveness, over-excitednessor other unusualchangesin

behaviour, worsening ofdepression orthinking aboutsuicide. Anysuchsymptomsshould bereported to

the patient’sdoctor, especiallyiftheyare severe, start suddenlyorwere not part ofthe patient’spresenting

symptomsbefore. You should evaluatetheemergence ofsuch symptomson adaytodaybasis,

especiallyearlyduring anti-depressant treatment and when the dose isincreased ordecreased,

sincechangesmaybe abrupt.

Symptomssuch asthese maybe associatedwith anincreased riskofsuicidalthinkingor behaviour and

indicate aneedfor veryclose monitoring and possible changesin medication.

3. HowtotakeAnafranil

The doctor willtellyou howmuch Anafranilto take and whento take it. Alwaysfollow thedoctor’sinstructions

carefully. The dose willbe onthepharmacist’slabel. Checkthelabelcarefully. Ifyouare not sure,

askyour doctor orpharmacist.

Takingthis medicine

Swallow your Anafranilcapsuleswhole with adrinkofwater.

Keeptaking your medicine untilyour doctor tellsyou tostop.Do notstop because you do not feelanybetter.

Thismedicinemaytake upto 4 weeksto work.

The medicine maybe taken asonedose atnight orastwo separate dosesduring the day.

Howmuch totake

The usualdosagesfor adultsare asfollows:

Fordepression: 1to 2tabletsdaily. Severe casesmayneedevenhigher doses.

Forobsessionsandphobias: 1 to2 tabletsdaily.

Forcataplexy: 1 tablet daily.

Ifyou are not sure how muchAnafranilto take, askyour doctor orpharmacist.

The elderly

Elderlypatientsoften needa lower dose because theyare more likelyto experience side effects.

Your doctor willtellyou aboutthis.

IfyoutakemoreAnafranilthanyoushould

Ifyou oranyoneelse, accidentlytakestoomuch Anafranil, tellyour doctor orgo to yournearest hospital

casualty

department immediately. Take yourmedicine packwith you so that people can see what you have taken.

IfyouforgettotakeAnafranil

Ifyou missa dose, take thenext dose atthe usualtime. Then goon asbefore. DONOTtake a double dose.

IfyoustoptakingAnafranil

Do notstop taking Anafranilsuddenlybecause thismaycause withdrawalside effects.Ifthedecision ismade

byyourdoctor to discontinuetreatment,thedose you willreceive willbe cut down graduallyto prevent the

development ofwithdrawalsymptoms. Youmaygetthese side effectsifyou stop taking Anafranilsuddenly:

feeling orbeing sick,stomach ache, diarrhoea, headache, difficultysleeping, nervousnessor anxiety.

Ifyou have anyfurtherquestionson the use ofthisproduct, askyour doctor orpharmacist.

4. Possible side effects

Like allmedicines, Anafranilcan cause side effects. The side effectsare usuallymildanddisappear as

treatment continues.

Some side effects canbe serious.

StoptakingAnafranil andtellyourdoctorimmediatelyifyounoticethe followingveryrare symptoms:

Rash, changesin bloodpressure, swelling and increased fluid in tissues, andincreased heart rate,

difficultywith breathing and collapse. These maybe signsofan allergicreaction.

Ahigh temperature and sweating with rigid musclesandconfusion oragitation, orifyou experience jerky

muscle movementswhich you can’t control. These maybe signsofaseriousconditionknown asneuroleptic

malignant syndrome.

The side effects listedbelowhave alsobeenreported:

Verycommon(More than 1in 10 people have experienced):

Increase in appetite and weight gain.

Headaches, dizziness, nausea, constipation, drymouth, increased sweating, shakinghands, tremor,

difficultyin passing urine, problemswith theireyes, feeling tiredor sleepy, sexualdisturbances, restlessness.

Common(Upto1 in 10 people have experienced):

Lossofappetite, stomach upset, vomiting, diarrhoea, light headednesswhenstandingup (due tolow blood

pressure), increased anxiety, agitation, hotflushes, enlarged pupils, speech disturbances, yawning, feeling

confused, disorientated or over excited,sleepdisturbances, nightmares, hallucinationsor thoughtdisturbances,

worsening ofexisting depression, impaired memoryandconcentration, aggressiveness, disturbancesin heart

rhythm, increased sensitivityoftheskin tosunlight,rash and itching, breast changes, numbnessor tingling in

the armsandlegs, muscle weakness, movementdisorder, changesin liver function tests, taste disturbances,

tinnitus(ringingin theears), swelling ofthebreastsanddischarge ofmilk, irritability, feeling detachedfroma

situation (like watching itfromafar).

Uncommon(Upto1 in 100peoplehave experienced):

Moodchangesincluding aggression,fits, movement disorders, increased bloodpressure, irregular heart

rhythm,

fever.

Veryrare (Upto1 in 10,000peoplehave experienced):

Glaucoma, hepatitiscausingjaundice (yellowing oftheskin or whitesoftheeyes), andlight coloured urine,

urinaryretention, oedema(generalisedswelling), hairloss, blooddisorders(which might result in persistent

sore throat,fever orfrequent infections, unexplainedbruising orbruising more easily).

Most ofthe side effects aremildandmaywearoffaftera fewdaystreatment. Iftheyare severeor

last more than afewdays,tellyourdoctor.Also, ifyourmedicineupsetsyouinanyotherway, tellyour

doctor.

Patientsaged 50yearsor older and taking amedicine ofthisgroup are more likelyto experience bone

fractures.

Children andAdolescents

Anafranilshould not beusedin thetreatment ofdepressive states, phobiasor cataplexyassociatedwith

narcolepsyin children and adultsunder the ageof18 yearsaslong-termsafetyeffectsconcerning growth,

maturation and cognitive andbehaviouraldevelopment ofAnafranilin thisagegroup have not yet been

demonstrated.

Also patientsunder 18 mayhave anincreased riskofside effectssuch assuicidalthoughts, harming

themselvesandhostility(predominantlyaggression, oppositionalbehavioursandanger)whentheytake drugs

like Anafranil. Despite this, your doctor mayprescribe Anafranilfor patientsunder 18 because theydecide that

thisisin theirbestinterests. Ifyour doctor hasprescribedAnafranilfor you (oryour child) and you wantto

discussthis, please gobackto your doctor.

You should informyour doctor ifanyofthesymptomslisted above develop orworsenwhen patients

under18 are taking Anafranil.

Also reported (frequencynotknown)

Feelingofinnerrestlessnessandacompellingneedtobeinconstantmotion,repetitive,involuntary,

purposelessmovements,breakdownofmuscle,increaseinprolactin(ahormone)levelintheblood,and

serotoninsyndrome(syndromecausedduetoincreaseinnaturallyoccurringmessenger,serotonin,in

brain;manifestedbysymptomslikeagitation,confusion,diarrhoea,hightemperature,increasedblood

pressure, excessive sweatingand rapid heartbeat),delayed orno ejaculation ofsemen ifyou are amale.

Reporting ofside effects

Ifyou get anyside effects, talkto your doctor, pharmacistor nurse. Thisincludesanypossible side effectsnot

listedin thisleaflet. You canalso report side effectsdirectlyvia HPRAPharmacovigilance, Earlsfort Terrace,

IRL-Dublin 2;Tel: +353 16764971;Fax: +353 16762517.Website: www.hpra.ie ; E-mail:

medsafety@hpra.ie . Byreporting side effectsyou can help providemore information on thesafetyofthis

medicine.

5. HowtostoreAnafranil

Keepout ofthereach and sight ofchildren.

Do notuse Anafranilafter the expirydate, which isstatedon the labelandcarton afterEXP.

The expirydaterefersto the last dayofthatmonth. Do not store above 30°C. Store in theoriginalpackage

in orderto protect frommoisture.

Ifyour doctor tellsyou tostop taking Anafranil, please take anyunused medicine backto your pharmacist to

be destroyed. Donotthrow it awaywith yournormalhousehold wateror waste. Thiswillhelp toprotect the

environment.

6. Furtherinformation

WhatAnafranil contains

The activesubstanceisclomipramine hydrochloride. Each prolonged releasefilm-coated tablet contains

75mg

clomipramine hydrochloride.

The other ingredientsare eudragit E30D, calciumhydrogenphosphate, silicon dioxide, calciumstearate,

hypromellose, red iron oxide (E172), polyoxylhydrogenated castor oil, talcandtitaniumdioxide (E171).

WhatAnafranil looks like andthecontentsofthe pack

Anafranil75 mg prolonged release Tabletsare ‘pink, capsule shaped, biconvex,film-coated tablets, scored on

bothsides. One side debossed with ‘CG’andtheother‘GD’. The tabletsshould not bebroken’.The tabletsare

formulatedto release theactive ingredient

slowly.

The tabletscome in packscontaining 28 tablets.

MarketingAuthorisationHolder

NovartisPharmaceuticalsUKLimited

FrimleyBusinessPark

Frimley

Camberley

Surrey

GU16 7SR

UK

Manufacturer

NovartisPharma SpA

Via ProvincialeSchito, 131

Torre Annunziata

Italy

Irish OfficeAddress:

NovartisIrelandLimited

Vista Building,

ElmParkBusinessPark,

Merrion Road

Dublin 4

Thisleaflet waslast revised inAugust 2015

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Anafranil SR 75 mg Prolonged-release Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 75mg clomipramine hydrochloride

Also contains polyoxyl hydrogenated Castor Oil, 190 micrograms per tablet

For a full list of excipients see section 6.1.

3 PHARMACEUTICAL FORM

Prolonged – release, film-coated tablet.

Pink,

capsule shaped,

biconvex,

film-coated tablet, scored on both sides.

One side debossed with ‘CG’ and the other

‘GD’.

The tablets should not be broken

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

In the management of endogenous depression including manic depression, periodic and involutional depression,

reactive and neurotic depression, obsessional and phobic states and as an adjunctive treatment of cataplexy associated

with narcolepsy.

4.2 Posology and method of administration

Before initiating treatment with Anafranil, hypokalemia should be treated (see 4.4 Special warnings and precautions for

use).

As a precaution against possible QTc prolongation and serotonergic toxicity, adherence to the recommended doses of

Anafranil is advised and any increase in dose should be made with caution if other serotonergic agents are co-

administered (see sections 4.4 Special Warnings and Precautions for use and 4.5 Interaction with other Medicinal

Products and other forms of Interaction).

The dosage should be adapted to the individual patient’s condition. The aim is to achieve an optimum effect while

keeping the doses as low as possible and increasing them cautiously. After a response has been obtained, maintenance

therapy should be continued at the optimum dose to avoid relapse. Patients with a history of recurrent depression

require maintenance treatment for a longer duration. Duration of maintenance treatment and need for further treatment

should be reviewed periodically.

Abrupt discontinuation of Anafranil therapy should be avoided because of possible withdrawal symptoms. Therefore,

dosage should be stopped gradually after regular use for long duration and the patient should be monitored carefully

when Anafranil therapy is discontinued.

Immediate release formulations (capsules) and sustained-release tablets can be used interchangeably in equivalent

doses.

Adults:

Depression:

The usual daily dosage is in the range of 30 to 75mg in single or divided doses. Initial dosage should be 10mg/day with

gradual increments to 30-150mg/day in divided doses or as a single dose at bedtime. Dosage may exceed the stated

range if necessary up to a maximum of 250mg.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

1

Obsessional/phobic states:

“The maintenance dosage of Anafranil is generally higher than that used in depression. It is recommended that the

dose be built up to 100-150mg Anafranil daily, according to the severity of the condition. This should be attained

gradually over a period of 2 weeks starting with 1 x 25mg Anafranil daily. In elderly patients and those sensitive to

tricyclic antidepressants a starting dose of 1 x 10mg Anafranil daily is recommended. Again where a higher dosage is

required the Sustained-release 75mg formulation may be preferable.”

Adjunctive treatment of cataplexy associated with narcolepsy:

Initially 10mg, increasing to 50mg daily. Control of cataplexy should be achieved within 24 hours of reaching optimal

dose.

Geriatric patients (aged 65 years and older)

Elderly patients generally show a stronger response to Anafranil than patients of intermediate age groups. Anafranil

should be used with caution in elderly patients and doses should be increased cautiously. Daily dose should generally

be low, initiated at the lowest level (10mg) with very slow cautious increments to 30-75mg daily.

Paediatric Patients

Anafranil is not recommended for use in children due to insufficient data on safety and/or efficacy” (See Section 4.4

Special Warnings and Precautions for use).

Renal impairment:

Anafranil should be given with caution in patients with renal impairment (see section 4.4 special warnings and

precautions for use and section 5 pharmacological properties).

Hepatic impairment:

Anafranil should be given with caution in patients with hepatic impairment (see section 4.4 special warnings and

precautions for use and section 5 pharmacological properties).

Anafranil prolonged-release tablets should be swallowed whole.

Anafranil can be administered with or without food.

4.3 Contraindications

Use in patients who are currently receiving, or have received within 3 weeks, monoamine oxidase inhibitors.

Use in patients in acute recovery phase of myocardial infarction.

Use in patients hypersensitive to dibenzazepines.

Use in patients with cardiac arrhythmias, particularly heartblock.

Use during lactation in women breast-feeding infants.

Use in mania, severe liver disease, narrow-angle glaucoma, and retention of urine.

Use in patients with congenital QT syndrome.

4.4 Special warnings and precautions for use

Suicide/suicidal thoughts or clinical worsening

Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This

risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of

treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the

risk of suicide may increase in the early stages of recovery.

Other psychiatric conditions for which Anafranil is prescribed can also be associated with an increased risk of suicide-

related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions

observed when treating patients with major depressive disorder should therefore be observed when treating patients

with other psychiatric disorders.

Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to

commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive

careful monitoring during treatment.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

2

A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders

showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years

old.

Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early

treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor

for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice

immediately if these symptoms present.

Modifying the therapeutic regimen, including possibly discontinuing the medication, should be considered in these

patients, especially if these changes are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.

Prescriptions for Anafranil should be written for the smallest quantity of tablets or capsules consistent with good patient

management, in order to reduce the risk of overdose.

Other Psychiatric effects

Many patients with panic disorder experience more marked anxiety at the start of treatment with Anafranil. This

paradoxical initial increase in anxiety is most pronounced during the first few days of treatment and generally subsides

within two weeks. Activation of psychosis has occasionally been observed in patients with schizophrenia receiving

tricyclic antidepressants. Hypomanic or manic episodes have also been reported during a depressive phase in patients

with cyclic affective disorders receiving treatment with a tricyclic antidepressant. In such cases it may be necessary to

reduce the dosage of Anafranil or to withdraw it and administer an antipsychotic agent. After such episodes have

subsided, low dose therapy with Anafranil may be resumed if required.

In predisposed patients, tricyclic antidepressants may provoke pharmacogenic (delirious) psychoses, particularly at

night. These disappear within a few days of withdrawing the drug.

Cardiac and vascular disorders

Anafranil should be administered with particular caution in patients with cardiovascular disorders, especially those with

cardiovascular insufficiency, conduction disorders, (e.g. atrioventricular block grades I to III), or arrhythmias.

Monitoring of cardiac function and the ECG is indicated in such patients.

There may be a risk of QTc prolongation and Torsades de Pointes, particularly at supratherapeutic doses or supra-

therapeutic plasma concentrations of clomipramine, as occur in the case of co-medication with selective serotonin

reuptake inhibitors (SSRIs) or serotonin and noradrenergic reuptake inhibitors (SNaRIs). Therefore, concomitant

administration of drugs that can cause accumulation of clomipramine should be avoided.

Equally, concomitant

administration of drugs that can prolong the QTc interval should be avoided (see sections 4.2 Posology and method of

administration and 4.5. Interactions with other medicinal products and other forms of interaction). It is established that

hypokalaemia is a risk-factor of QTc prolongation and Torsades de pointes. Therefore, hypokalaemia should be treated

before initiating treatment with Anafranil and Anafranil should be used with caution when combined with SSRIs,

SNaRIs or diuretics (see section 4.5)

Tricyclic antidepressants are known to lower the convulsion threshold and Anafranil should therefore be used with

extreme caution in patients with epilepsy and other predisposing factors, e.g. brain damage of varying aetiology,

concomitant use of neuroleptics, withdrawal from alcohol or drugs with anticonvulsive properties (e.g.

benzodiazepines). It appears that the occurrence of seizures is dose dependent, therefore the recommended total daily dose

of Anafranil should not be exceeded.

Caution is called for when giving tricyclic antidepressants to patients with with severe hepatic disease and tumours of the

adrenal medulla (e.g. phaeochromocytoma, neuroblastoma), in whom they may provoke hypertensive crises.

Concomitant treatment of Anafranil and electroconvulsive therapy should only be resorted to under careful supervision.

Elderly patients are particularly liable to experience adverse effects, especially agitation, confusion, and postural

hypotension.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

3

Precautions:

Before initiating treatment it is advisable to check the patient’s blood pressure, because individuals with hypotension or a

labile circulation may react to the drug with a fall in blood pressure.

White Blood cell Count

Although changes in the white blood cell count have been reported with Anafranil only in isolated cases, periodic blood

cell counts and monitoring for symptoms such as fever and sore throat are called for, particularly during the first few

months of therapy. They are also recommended during prolonged therapy.

It is advisable to monitor cardiac and hepatic function during long-term therapy with Anafranil. In patients with hepatic

and renal disease, periodic monitoring of the hepatic enzyme levels and renal function is recommended.

Anticholinergic effects

Because of its anticholinergic properties, Anafranil should be used with caution in patients with a history of increased

intra-ocular pressure, narrow angle glaucoma or urinary retention) e.g. diseases of the prostate).

Specific treatment populations

Caution is indicated in patients with hyperthyroidism or during concomitant treatment with thyroid preparations since

aggravation of unwanted cardiac effects may occur.

Caution should be exercised when using Anafranil in patients with severe renal disease.

In elderly patients, tricyclic antidepressants may provoke pharmacogenic (delirious) psychoses, particularly at night.

These disappear within a few days of withdrawing the drug.

Monitoring of cardiac function and the ECG is indicated in elderly patients.

An increase in dental caries has been reported during long-term treatment with tricyclic antidepressants. Regular dental

check-ups are therefore advisable during long-term treatment.

Long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural

development are not available. Anafranil is not recommended for use in children due to insufficient data on safety and/or

efficacy.

Caution is called for in patients with chronic constipation. Tricyclic antidepressants may cause paralytic ileus, particularly

in the elderly and in bedridden patients.

Decreased lacrimation and accumulation of mucoid secretions due to the anticholinergic properties of trycyclic

antidepressants may cause damage to the corneal epithelium in patients with contact lenses.

The excipient polyoxyl hydrogenated castor oil may cause stomach upset and diarrhoea.

Risk of suicide is inherent to severe depression and may persist until significant remission occurs. Patients posing a high

suicide risk require close initial supervision.

Anaesthesia

Before general or local anaesthesia, the anaesthetist should be aware that the patient has been receiving Anafranil and of

the possible interactions (see 4.5 Interaction with other medicaments and other forms of interaction).

Treatment Discontinuation

Abrupt withdrawal should be avoided because of possible adverse reactions (see 4.8 Undesirable Effects). If the decision

has been made to discontinue treatment, medication should be tapered as rapidly as is feasible, but with recognition that

abrupt discontinuation can be associated with certain symptoms (see section 4.8 Undesirable effects for a description of

the risks of discontinuation of Anafranil).

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

4

4.5 Interaction with other medicinal products and other forms of interaction

Adrenergic neurone blockers: Anafranil may diminish or abolish the antihypertensive effects of guanethidine,

betanidine, reserpine, clonidine and alpha-methyldopa. Patients requiring comedication for hypertension should

therefore be given antihypertensives of a different type (e.g. vasodilators, or beta-blockers).

Anticholinergic agents: Tricyclic antidepressants may potentiate the effects of these drugs (e.g. phenothiazine,

antiparkinsonian agents, antihistamines, atropine, biperiden) on the eye, central nervous system, bowel and bladder.

CNS depressants: Tricyclic antidepressants may potentiate the effects of alcohol and other central depressant

substances (e.g. barbiturates, benzodiazepines, or general anaesthetics).

Diuretics

Comedication of Anafranil with diuretics may lead to hypokalemia, which in turn increases the risk of QTc prolongation

and Torsades de Pointes. Hypokalaemia should therefore be treated prior to administration of Anafranil (see 4.2 Posology

and 4.4 Special warnings and precautions).

MAO inhibitors: Do not give Anafranil for at least 3 weeks after discontinuation of treatment with MAO inhibitors

(there is a risk of severe symptoms such as hypertensive crisis, hyperpyrexia and those consistent with Serotonin

Syndrome e.g. myoclonus, agitation, seizures, delirium and coma). The same applies when giving a MAO inhibitor

after previous treatment with Anafranil. In both instances the treatment should initially be given in small gradually

increasing doses and its effects monitored. There is evidence to suggest that Anafranil may be given as little as 24

hours after a reversible MAO-A inhibitor such as moclobemide, but the 3 week wash-out period must be observed if

the MAO-A inhibitor is used after Anafranil.

Selective serotonin reuptake inhibitors: Co-medication with SSRI’s may lead to additive effects on the serotonin

system (see serotonergic agents)

Serotenergic Agents: Seretonin Syndrome can possible occur when clomipramine is administered with serotonergic co-

medications such as slective serotonin re-uptake inhibitors (SSRIs), serotonin and nonadrenergic reuptake inhibitors

SNaRI’s), tricyclic antidepressants –or lithium. For fluoxetine, a washout period of two to three weeks is advised

before and after treatment with fluoxetine.

Sympathomimetic drugs: Anafranil may potentiate the cardiovascular effects of adrenaline, ephedrine, isoprenaline,

noradrenaline, phenylephrine, and phenylpropanolamine (e.g. as contained in local and general anaesthetic preparations

and nasal decongestants).

Pharmacokinetic-related interactions:

Anafranil (clomapramine) is predominantly eliminated through metabolism. The primary route of metabolism is

demethylation to form the active metabolite, N-desmethylclomipramine, followed by hydroxylation and further

conjugation of both N-desmethylclomipramine and the parent drug. Several cytochrome P450’s are involved in the

desmethylation, mainly CYP3A4, CYP2C19 and CYP1A2. Elimination of both active components is by hydroxylation

and its catalyzed by CYP2D6.

Concomitant administration of CYP2D6 inhibitors may lead to an increase in concentration of both active components,

up to

3 fold in patients with desbrinoquine/sparteine extensive metabolizer phenotype, converting them to poor-

metabolizer phenotype. Concomitant administration of CYP1A2, CYP2C19 and CYP3A4 inhibitors are expected to

increase clomipramine concerntrations and decrease N-desmethylclomipramine, thus not necessarily affecting the

overall pharmacology.

MAO inhibitors which are also potent CYP2D6 inhibitors in vivo, such as moclobemide,

are contraindicated for coadministration with clomipramine.

Antiarrhythmics (such as quinidine and propafenone), which are potent inhibitors of CYP2D6, should not

be used in combination with tricyclic antidepressants.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

5

SSRI’s, which are inhibitors of CYP2D6, such as fluoxetine, paroxetine or sertraline and of others

including CYP1A and CYP2C19 (e.g. Fluvoxamine) may also increase plasma concentrations of

clomipramine, with corresponding adverse effects. Steady-state serum levels of clomipramine increased

4 fold by co-administration of fluvoxamine (N-desmethylclomipramine decreased

2 fold)

Comedication of antipsychotics (e.g.phenothiazines) may result in increased plasma levels of tricyclic

antidepressants, a lowered convulsion threshold and seizures. Combination with thioridazine may produce

severe cardiac arrhythmias.

Oral antifungal, terbinafine. Coadministration of Anafranil with terbinafine, a strong inhibitor of CYP2D6,

may result in increased exposure and accumulation of clomipramine and its N-demethylated metabolite.

Therefore, dose adjustments of Anafranil may be necessary when coadministered with terbinafine.

Coadministration with the histamine

) receptor antagonist, cimetidine (an inhibitor of several P450

enzymes, including CYP2D6 and CYP3A4), may increase plasma concentrations of tricyclic

antidepressants, whose dosage should therefore be reduced.

No interaction between chronic oral contraceptive use (15 or 30 mg ethinyl estradiol daily) and Anafranil

(25 mg daily) has been documented. Estrogens are not known to be inhibitors of CYP2D6, the major

enzyme involved in clomipramine clearance and therefore, no interaction is expected. Although in a few

cases with high dose estrogen (50 mg daily) and the tricyclic antidepressant imipramine, increased side

effects and therapeutic response were noted, it is unclear as to the relevance of these cases to clomipramine

and lower dose estrogen regimens. Monitoring therapeutic response of tricyclic antidepressants at high

dose estrogen regimems (50 mg daily) is recommended and dose adjustments may be necessary.

Methylphenidate (e.g. Ritalin) may also increase concentrations of tricyclic antidepressants by potentially

inhibiting their metabolism, and a dose reduction of tricyclic antidepressant may be necessary.

Concomitant administration of valproate with clomipramine may cause inhibition of CYP2C and/or UGT

enzymes resulting in increased serum levels of clomipramine and desmethylclomipramine.

Comcomitant administration of Anafranil with grapefruit, grapefruit juice or cranberry juice my increase

the plasma concentrations of clomipramine.

Some tricyclic antidepressants may potentiate the anticoagulant effect of coumarin drugs, such as warfarin, and this

may be through inhibition of their metabolism (CYP2C9). There is no evidence for the ability of clomipramine to

inhibit the metabolism of anticoagulants, such as warfarin, however, careful monitoring of plasma prothrombin has

been advised for this class of drug.

Concomitant administration of drugs known to induce cytochrome P450 enzymes, particularly CYP3A4,

CYP2C19, and/or CYP1A2 may accelerate the metabolism and decrease the efficacy of Anafranil.

CYP3A and CYP2C inducers such as rifampicin or anticonvulsants (e.g. barbiturates, carbamazepine,

phenobarbital and phenytoin), may decrease clomipramine concentrations.

Known inducers of CYP1A2 (e.g. nicotine/components in cigarette smoke), decrease plasma

concentrations of tricyclic drugs. In cigarette smokers, clomipramine steady-state plasma concentrations

were decreased 2 fold compared to non-smokers (no change in N-desmethylclomipramine).

Concomitant administration of ion exchange resins such as cholestyramine or colestipol may reduce the

plasma levels of clomipramine. Staggering the dosage of clomipramine and resins, such that the drug is

administered at least 2 h before or 4-6 h after the administration of resins, is recommended.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

6

Concomitant administration of Anafranil with St. John’s wort during the treatment may decrease the plasma

concentrations of clomipramine.

Clomipramine is also an in vitro (K

= 2.2µM) and in vivo inhibitor of CYP2D6 activity (sparteine oxidation) and

therefore, may cause increased concentrations of co-administered compounds that are primarily cleared by CYP2D6 in

extensive metabolizers.

4.6 Fertility, pregnancy and lactation

Women of child-bearing potential

There are no data supporting any special recommendations in women of child-bearing potential.

Pregnancy

There is limited amount of data from the use of Anafranil in pregnant women that indicates a potential to harm the

foetus or cause congenital malformation. Anafranil should be used during pregnancy only if the potential benefit

outweighs the potential risk to the foetus.

Neonates whose mothers had taken tricyclic antidepressants until delivery showed drug withdrawal symptoms, such as

dyspnoea, lethargy, colic, irritability, hypotension or hypertension, and tremor /convulsions, during the first few hours

or days. To avoid such symptoms, Anafranil should if possible be gradually withdrawn at least 7 weeks before the

calculated date of confinement.

Lactation

Since the active substance passes into breast milk, Anafranil should be gradually withdrawn or the infant weaned if the

patient is breast-feeding.

Fertility

No adverse effects on reproductive performance, including male and female fertility, were observed in rats at oral doses

up to 24 mg/kg.

No teratogenic effects were detected in mice, rats, and rabbits at doses up to 100, 50, and 60 mg/kg, respectively (see

section 5.3 Preclinical safety data).

4.7 Effects on ability to drive and use machines

Patients receiving Anafranil should be warned that blurred vision, and other nervous system and psychiatric related

disorders such as somnolence, disturbance in attention, confusion, disorientation, aggravation of depression, delirium

etc, have been observed. In the presence of such effects, patients should not drive or operate machinery or do anything

else which may require alertness or quick actions.

4.8 Undesirable effects

Unwanted effects are usually mild and transient, disappearing under continued treatment or with a reduction in the

dosage. They do not always correlate with plasma drug levels or dose. It is often difficult to distinguish certain

undesirable effects from symptoms of depression such as fatigue, sleep disturbances, agitation, anxiety, constipation,

and dry mouth.

If severe neurological or psychiatric reactions occur, Anafranil should be withdrawn.

Frequency estimates: Very common

10%, common

1% to <10%, uncommon

0.1% to <1%, rare

0.01% to

<0.1%, very rare <0.01%. The ADRs listed below are based on clinical trials as well as post marketing reports.

Blood and lymphatic system disorders

Very rare

leukopenia, agranulocytosis, thrombocytopenia, eosinophilia

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

7

Cardiac disorders

Common

sinus tachycardia, palpitations, orthostatic hypotension, clinically irrelevant ECG changes (e.g.

ST and T changes) in patients of normal cardiac status

Uncommon

arrhythmias, blood pressure increased

Very rare

conduction disorders (e.g. widening of QRS complex, prolonged QT interval, PQ changes,

bundle-branch block, Torsade de Pointes, particularly in patients with hypokalaemia)

Ear and labyrinth disorders

Common

tinnitus

Endocrine disorders

Very rare

SIADH (inappropriate antidiuretic hormone secretion syndrome)

Eye disorders

Very common

accomodation disorder, vision blurred

Common

mydriasis

Very rare

glaucoma

Gastrointestinal disorder

Very common

nausea, dry mouth, constipation

Common

vomiting, gastrointestinal disorder, diarrhoea

General disorders and administration site conditions

Very common

fatigue

Very rare

oedema (local or generalised), alopecia, hyperpyrexia

Hepatobiliary disorders

Very rare

hepatitis with or without jaundice.

Immune system disorders

Very rare

systemic anaphylactic and anaphylactoid reactions including hypotension

Investigations

Very common

weight increased

Common

transaminases increased

Very rare

electroencephalogram abnormal

Metabolism and nutrition disorders

Very common

increased appetite

Common

decreased appetitie

Musculoskeletal and connective tissue disorders

Common

muscular weakness

Nervous system disorders

Very common

dizziness, tremor, headache, myoclonus, somnolence

Common

speech disorders, paraesthesia, hypertonia, dysgeusia, memory impairment, disturbance in

attention

Uncommon

convulsions, ataxia

Very rare

neuroleptic malignant syndrome

Psychiatric disorders

Very common

restlessness

Common

confusional state, disorientation, hallucinations (particularly in elderly patients and patients with

Parkinson’s disease), anxiety, agitation, sleep disorder, mania, hypomania, aggression,

depersonalisation, aggravation of depression,

insomnia, nightmares, delirium

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

8

Uncommon

activation of psychotic symptoms

Unknown

suicidal ideation* and suicidal behaviour*

* Cases of suicidal ideation and suicidal behaviours have been reported during clomipramine therapy or early after

treatment discontinuation (see section 4.4)

Renal and urinary disorders

Very common

micturition disorder

Very rare

urinary retention

Reproductive system and breast disorders

Very common

libido disorder, erectile dysfunction

Common

galactorrhoea, breast enlargement

Respiratory, thoracic and mediastinal disorders

Common

yawning

Very rare

alveolitis (pneumonitis) with or without eosinophilia

Skin and subcutaneous tissue disorders

Very common

hyperhidrosis

Common

dermatitis allergic (skin rash, urticaria), photosensitivity reaction, pruritus

Very rare

purpura

Vascular disorders

Common

hot flush

Additional adverse drug reaction from port-marketing spontaneous reports

The following additional adverse drug reactions have been identified with Anafranil oral or IM/IV dosage forms based

on post-marketing spontaneous reports. Because these reactions are reported voluntarily from a population of uncertain

size, it is not always possible to reliably estimate their frequency.

Nervous system disorders

Frequency not known: Serotonin syndrome, extrapyramidal symptoms (including akathisia and tardive dyskinesia)

Musculoskeletal and connective tissue disorders

Frequency not known: Rhabdomyolysis (as a complication of neuroleptic malignant syndrome)

Reproductive system and breast disorders

Frequency not known: Ejaculation failure, Ejaculation delayed

Investigations

Frequency not known: Blood prolactin increased

Bone fractures

Epidemiological studies, mainly in patients 50 years of age and older, show an increased risk of bone fractures in

patients receiving SSRIs and TCAs. The mechanism leading to the risk is unknown.

Withdrawal symptoms The following symptoms commonly occur after abrupt withdrawal or reduction of the dose:

nausea, vomiting, abdominal pain, diarrhoea, insomnia, headache, nervousness, and anxiety.

Geriatric population

Elderly patients are particularly sensitive to anticholinergic, neurological, psychiatric or cardiovascular effects. Their

ability to metabolise and eliminate drugs may be reduced, leading to a risk of elevated plasma concentrations at

therapeutic doses.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

9

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued

monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any

suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971;

Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

4.9 Overdose

The signs and symptoms of overdose with Anafranil are similar to those reported with other tricyclic antidepressants.

Cardiac abnormalities and neurological disturbances are the main complications. In children accidental ingestion of any

amount should be regarded as serious and potentially fatal.

Signs and symptoms

Symptoms generally appear within 4 hours of ingestion and reach maximum severity after 24 hours. Owing to delayed

absorption (anticholinergic effect), long half-fife, and enterohepatic recycling of the drug, the patient may be at risk for

up to 4-6 days.

The following signs and symptoms may be seen:

Central nervous system

Somnolence, stupor, coma, ataxia, restlessness, agitation, hyperreflexia, muscle rigidity and choreoathetosis

movements, convulsions. In addition, symptoms consistent with Serotonin Syndrome (e.g. hyperpyrexia, myoclonus,

delirium and coma) may be observed.

Cardiovascular system

Hypotension, tachycardia, arrhythmias, QTc prolongation and arrhythmias including Torsades de Pointes, conduction

disorders, shock, heart failure; in very rare cases cardiac arrest.

Respiratory depression, cyanosis, vomiting, fever, mydriasis, sweating, and oliguria or anuria may also occur.

Treatment

There is no specific antidote, and treatment is essentially symptomatic and supportive.

Anyone suspected of receiving an overdose of Anafranil, particularly children, should be hospitalised and kept under

close surveillance for at least 72 hours.

Perform gastric lavage or induce vomiting as soon as possible if the patient is alert. If the patient is not alert, secure the

airway with a cuffed endotracheal tube before beginning lavage, and do not induce vomiting. These measures are

recommended for up to 12 hours or ever longer after the overdose, since the anticholinergic effect of the drug may help

to reduce drug absorption.

Since it has been reported that phyotigmine may cause severe bradycardia, asystole, and seizures, it’s use is not

recommended in cases of overdosage with Anafranil. Haemodialysis or peritoneal dialysis are ineffective because of

the low plasma concentrations of clomipramine.

Rare cases of pharmacobezoar, of varying severity including fatal outcome, have been reported in association with

overdose of sustained release Anafranil. The pharmacobezoar may be radiopaque, facilitating radiologic (X-ray or CT

scan) confirmation but cannot exclude the diagnosis. The formation of pharmacobezoar may cause slow but continual

release and absorption of clomipramine which may lead to overdose complications, including death, hours after drug

ingestion and initial treatment with gastric lavage and activated charcoal. Since gastric lavage may be ineffective and

could further increase systemic drug levels, consideration should be given to physical removal of the pharmacobezoar

by endoscopy or surgery in selected patients. Since these cases are rare, there is insufficient clinical data regarding

optimal treatment which should take into account the size and location of the pharmacobezoar, patient symptoms and

condition and drug levels.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

1

0

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group

Tricyclic antidepressant, ATC code: N06A A04

Mechanism of action

The pharmacological action includes alpha-adrenolytic, anticholinergic, anti-histaminic and 5-HT receptor blocking

properties. The main property displayed by the compound is its ability to inhibit the neuronal re-uptake of

noradrenaline and 5-HT. Inhibition of the latter is the dominant component.

5.2 Pharmacokinetic properties

Absorption:

The active substance is completely absorbed following oral administration and intramuscular injection.

The systemic bioavailability of unchanged clomipramine is reduced by 50% by hepatic "first-pass" metabolism to

desmethylclomipramine (an active metabolite).

Following single dose administration 25 mg coated tablet and 75 mg sustained release tablet, the mean maximum

plasma concentration (Cmax) of clomipramine were 63.37 ± 12.71 ng/mL (Tmax 4.83 ± 0.39 hr) and 32.55 ± 8.10

(Tmax 9.00 ± 1.81 hr), respectively. The dose of 75mg Anafranil daily produces steady state concentrations of

clomipramine ranging from about 20 to 175ng/ml. The steady state plasma concentrations of the active metabolit N-

desmethylclomipramine follow a similar pattern, but are 40-85% higher than those of clomipramine.

Distribution:

Clomipramine is 97.6% bound to plasma proteins. Clomipramine is extensively distributed throughout the body with

the apparent volume of distribution of about 12-17 L/kg bodyweight. Concentrations in cerebrospinal fluid are about

2% of the plasma concentration.

Clomipramine passes into maternal milk in concentrations similar to those in plasma

and crosses the placenta.

Metabolism:

The primary route of clomipramine metabolism is demethylation to form the active metabolite, N-

desmethylclomipramine. N-desmethylclomipramine can be formed by several P450 enzymes, primary CYP3A4,

CYP2C19, and CYP1A2. Clomipramine and N-desmethylclomipramine are hydroxylated to form 8-

hydroxyclomipramine or 8-hydroxy-N-desmethylclomipramine. Clomipramine is also hydroxylated at the 2-position

and N-desmethylclomipramine can be further demethylated to form didesmethylclomipramine. The 2- and 8-hydroxy

metabolites are excreted primarily as glucuronides in the urine. Elimination of the active components, clomipramine

and N-desmethylclomipramine, by formation of 2-and 8-hydroxy clomipramine is catalysed by CYP2D6.

Elimination:

Oral clomipramine is eliminated from the blood with a mean half-life of 21 hours (range 12-36 h), and

desmethylclomipramine with a half-life of 36 hours.

About two-thirds of a single dose of clomipramine is excreted in the form of water-soluble conjugates in the urine, and

approximately one-third in the faeces. The quantity of unchanged clomipramine and desmethylclomipramine excreted

in the urine amounts to about 2% and 0.5% of the administered dose respectively.

Food effect

Food has no significant impact on the pharmacokinetics of clomipramine. A slight delay in the onset of absorption may

be observed with the administration of Anafranil with food.

Dose proportionality

The drug follows dose-proportionate pharmacokinetics over a dose range of 25 to 150 mg.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

1

1

Effect of age

In elderly patients, clomipramine has relatively low clearance in comparison to younger adult patients. It is reported to

reach a therapeutic steady state at doses lower than that reported for middle-age patients. Clomipramine should be used

with caution in elderly patients.

Renal impairment

There are no specific reports describing the pharmacokinetic of the drug in patients with renal impairment. Although

the drug is excreted as inactive metabolites in the urine and faeces, the accumulation of inactive metabolites may

subsequently result in the accumulation of the parent drug and its active metabolite. In moderate and severe renal

impairment, it is recommended to monitor the patient during the treatment.

Hepatic impairment

Clomipramine is extensively metabolized in the liver by CYP2D6, CYP3A4, CYP2C19 and CYP1A2, hepatic

impairment may impact on its pharmacokinetics. In patients with liver impairment, clomipramine should be

administered with caution.

Ethnic sensitivity

Although the impact of ethnic sensitivity and race on the pharmacokinetics of clomipramine has not been studied

extensively, the metabolism of clomipramine and its active metabolite is governed by genetic factors leading to poor

and extensive metabolism of the drug and its metabolite. The metabolism of clomipramine in Caucasians population

may not be extrapolated to Asians, in particular, Japanese and Chinese because of the pronounced differences of

metabolism of clomipramine between these two ethnic groups.

Sustained release formulation

Sustained release of clomipramine from Anafranil sustained release formulation provides a smoother pharmacokinetic

profile by maintaining therapeutic plasma concentrations over 24 hours. Maximum mean plasma concentrations are

reached within about 9 hours post-dose. Following administration of 75 mg clomipramine as sustained release

formulation, observed Cmax is half the maximum concentration levels reached after administration of 25 mg tablets

three times a day. Nevertheless, the total exposure remains unchanged. Following multiple administration of sustained

release formulation, Cmin and Cmax levels attained at steady state are within the therapeutic range. Sustained-release

tablets are bioequivalent with coated tablets and capsules.

5.3 Preclinical safety data

Repeat-dose toxicity

Phospholipidosis and testicular changes, commonly associated with tricyclic compounds, have been observed with

clomipramine hydrochloride at doses >10 fold greater than the maximum recommended human daily dose (MRHD).

Reproductive toxicity

No adverse effects on reproductive performance, including male and female fertility, were observed in rats at oral doses

up to 24 mg/kg.

No teratogenic effects were detected in mice, rats, and rabbits at doses up to 100, 50, and 60 mg/kg, respectively.

Mutagenicity

Various in vitro and in vivo mutagenicity tests were performed and did not reveal any mutagenic activity of

clomipramine hydrochloride.

Carcinogenicity

There was no evidence of carcinogenicity in mice and rats after 104 weeks of treatment with clomipramine

hydrochloride.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

1

2

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Eudragit E30D (polyacrylate dispersion 30%)

Calcium hydrogen phosphate

Silicon dioxide

Calcium stearate

Hypromellose

Red iron oxide (E172)

Castor oil, polyoxyl hydrogenated

Talc

Titanium dioxide (E171).

6.2 Incompatibilities

Not applicable

6.3 Shelf life

5 years.

6.4 Special precautions for storage

Do not store above 30°C. Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

PVC/Aluminium blister packs in cardboard cartons.

Pack sizes of 100 capsules and 28 capsules are available.

Not all pack sizes may be marketed

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from

such medicinal product and other handling of the product

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Novartis Pharmaceuticals UK Ltd.

Frimley Business Park

Frimley

Camberley

Surrey

GU16 7SR

England

8 MARKETING AUTHORISATION NUMBER

PA0013/084/006

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

1

3

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 19 September 1988

Date of last renewal: 01 April 2008

10 DATE OF REVISION OF THE TEXT

August 2015

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

1

8

/

0

7

/

2

0

1

7

C

R

N

2

1

9

3

9

6

0

p

a

g

e

n

u

m

b

e

r

:

1

4

Similar products

Search alerts related to this product

View documents history

Share this information